<DOC>
	<DOCNO>NCT00381472</DOCNO>
	<brief_summary>The purpose double-blind , placebo control study evaluate safety effectiveness investigational Parkinson 's disease drug patient advanced disease well-controlled L-dopa medication .</brief_summary>
	<brief_title>Investigational Parkinson 's Disease In Patients Not Well Controlled On L-dopa</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Idiopathic Parkinson 's disease Modified Hoehn Yahr Scale Stages II IV Stable dose Ldopa least 4 week prior screen . Lack control Ldopa therapy . Women childbearing potential must use clinically accepted form birth control . Significant and/or uncontrolled medical condition ( exclude Parkinson 's disease ) within 3 month screen . Any abnormality , screening , consider clinically relevant Investigator . Dementia Use dopamine agonist within 4 week screen visit . Participation investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Adjunctive Therapy L-dopa</keyword>
</DOC>